Spero Therapeutics (SPRO) Total Current Liabilities (2016 - 2026)

Spero Therapeutics (SPRO) has reported Total Current Liabilities for 11 consecutive years, with $8.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 43.61% year-over-year to $8.4 million; the trailing twelve-month figure through Jun 2026 stood at $8.4 million (down 43.61% YoY), and the FY2025 full-year result was $8.9 million, down 81.93% from the prior year.
• Total Current Liabilities climbed to $8.4 million in Q2 2026 per SPRO's latest filing, from $5.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $69.2 million in Q1 2022 and bottomed at $5.5 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $27.2 million across 5 years, with a median of $22.3 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 289.57% in 2022, then sank 81.93% in 2025.
• Over 5 years, Total Current Liabilities stood at $21.6 million in 2022, then surged by 71.62% to $37.2 million in 2023, then jumped by 32.09% to $49.1 million in 2024, then tumbled by 81.93% to $8.9 million in 2025, then declined by 4.96% to $8.4 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $8.4 million, $5.5 million, and $8.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.